Product Pathways
BCP0001 GDC-0941
GDC-0941 is a potent inhibitor of PI3Kα, PI3Kβ, PI3Kδ and PI3Kγ ;10G in stock
BCP0008 GSK690693
aminofurazan-derived inhibitor of Akt kinases with potential antine
BCP0027 BEZ235
Orally active PI3K tyrosine kinase inhibitor
BCP0102 PL-100
PL-100 is a novel HIV-1 protease inhibitor (PI) with a favorable cross-resistance profile and high genetic barrier.
BCP0107 Rapamycin
Rapamycin (Sirolimus, AY-22989, WY-090217) is a specific mTOR inhibitor.
BCP0113 SB216763
SB216763 is a potent and selective GSK-3α inhibitor.
BCP0125 Temsirolimus
Temsirolimus (also known as CCI-779) is a recently developed mTOR inhibitor.
BCP0049 Deforolimus
Deforolimus (Ridaforolimus, AP23573, MK-8669) is a selective mTOR inhibitor.
BCP0056 Everolimus(RAD001)
Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM.
BCP0070 LY 294002
LY 294002 has been shown to be a potent inhibitor of PI 3-kinase activity, acting as a competitive inhibitor for ATP binding site of the enzyme.
第一页 1 2 3 4 5 6 7 8 9 10 下10页 最后页 
Only for research purpose , not for human consumption Copyright©2012 ShangHai Biochempartner Co.,Ltd.